diffuse panbronchiolitis dpb inflammatory lung disease unknown cause severe progressive form bronchiolitis inflammatory condition bronchioles small air passages lungs term diffuse signifies lesions appear throughout lungs panbronchiolitis refers inflammation found layers respiratory bronchioles involved gas exchange dpb causes severe inflammation nodulelike lesions terminal bronchioles chronic sinusitis intense coughing large amounts sputum production disease believed occur susceptibility lack immune system resistance dpbcausing bacteria viruses caused several genes found predominantly individuals east asian descent highest incidence occurs among japanese people followed koreans dpb occurs often males usually begins around age recognized distinct new disease early formally named diffuse panbronchiolitis left untreated dpb progresses bronchiectasis irreversible lung condition involves enlargement bronchioles pooling mucus bronchiolar passages daily treatment dpb macrolide antibiotics erythromycin eases symptoms increases survival time disease currently known cure eventual result dpb respiratory failure heart problems term bronchiolitis generally refers inflammation dpb classified form primary bronchiolitis means underlying cause bronchiolitis originating confined along dpb additional forms primary bronchiolitis include bronchiolitis obliterans follicular bronchiolitis respiratory bronchiolitis mineral dust airway disease number unlike dpb bronchiolitis considered primary would associated diseases larger airways chronic symptoms dpb include chronic sinusitis inflamed paranasal sinuses wheezing crackles respiratory sounds made obstructions phlegm secretions lungs dyspnea shortness breath severe cough yields large amounts sputum coughedup phlegm may pus sputum affected individuals may fever typical signs dpb progression include dilation enlargement bronchiolar passages hypoxemia low levels oxygen blood dpb left untreated bronchiectasis occur characterized dilation thickening walls bronchioles inflammatory damage respiratory terminal bronchioles pooling mucus dpb associated progressive respiratory failure hypercapnia increased levels carbon dioxide blood eventually lead pulmonary hypertension high blood pressure pulmonary vein artery cor pulmonale dilation right ventricle heart right heart dpb idiopathic means exact physiological environmental pathogenic cause disease unknown however several factors suspected involved pathogenesis way disease major histocompatibility complex mhc large genomic region found vertebrates associated immune system located chromosome humans subset mhc humans human leukocyte antigen hla controls antigenpresenting system part adaptive immunity pathogens bacteria viruses human cells infected pathogen present parts pathogens proteins surfaces called antigen presentation infected cells become targets types cytotoxic tcells kill infected cells removed genetic predisposition dpb susceptibility localized two hla haplotypes nucleotide gene sequence difference paired chromosomes likely occur among common ethnicity trait common people east asian descent associated dpb japanese associated disease several genes within region class hla believed responsible dpb allowing increased susceptibility common genetic background similarities hla profile affected japanese korean individuals considered search dpb suggested mutation suspected diseasesusceptibility gene located somewhere occurred ancestral chromosome carrying possible number genetic recombination events around disease locus location chromosome could resulted disease associated japanese koreans study concluded dpb susceptibility gene located near hlab locus chromosome within area search genetic cause disease many genes belonging hla remain unidentified positional cloning method used identify specific gene location chromosome known used determine mucinlike gene associated dpb addition diseases caused identified hla genes dpbsusceptibility region investigated one bare lymphocyte syndrome bls exhibits number similarities dpb affected including chronic sinusitis bronchiolar inflammation nodules presence h influenzae also like dpb bls responds favorably erythromycin therapy showing resolution symptoms similarities two diseases corresponding success mode treatment fact gene responsible bls located within dpbcausing area hla narrows establishment gene responsible environmental factors inhaling toxic fumes cigarette smoking believed play role dpb unknown environmental nongenetic unidentified bacteria ruled cystic fibrosis cf progressive multisystem lung disease considered search genetic cause dpb number reasons cf like dpb causes severe lung inflammation abundant mucus production infection shows genetic predominance among caucasians one geographic group rarity others whereas dpb dominates among east asians cf mainly affects individuals european descent gene implicated cause dpb mutation specific likely occur cf mutation cfcausing gene factor dpb unique polymorphism variation gene known occur many asians necessarily affected either disease investigated whether gene state mutation could contribute inflammation normal part human immune response whereby leukocytes white blood cells including neutrophils white blood cells specialize causing inflammation gather chemokines proteins released certain cells activate elicit response cells accumulate location body bacterial viral infections occur inflammation interferes activity bacteria viruses serves clear body dpb bacteria haemophilus influenzae pseudomonas aeruginosa cause proliferation inflammatory cells bronchiolar tissues however neither bacteria present dpb inflammation continues yet unknown either circumstance inflammation dpb severe nodules containing inflammatory cells form walls presence inflammation infection airways also results production excess mucus must coughed combination inflammation nodule development infection mucus frequent cough contributes breathing difficulties fact inflammation dpb persists without presence p aeruginosa h influenzae provides means determine several mechanisms dpb leukotrienes eicosanoids signaling molecules made essential fatty acids play role many lung diseases causing proliferation inflammatory cells excess mucus production dpb lung diseases predominant mediator neutrophilrelated inflammation leukotriene specializes neutrophil proliferation via chemotaxis movement types cells toward away certain inflammation dpb also caused chemokine involvement cells beta defensins family antimicrobial peptides found respiratory tract responsible inflammation dpb pathogen p aeruginosa present present dpb human tlymphotropic virus type retrovirus modifies dpb pathogenesis infecting helper cells altering effectiveness recognizing presence known unknown pathogens involved diagnosis dpb requires analysis lungs bronchiolar tissues require lung biopsy preferred high resolution computed tomography hrct scan diagnostic criteria include severe inflammation layers respiratory bronchioles lung tissue lesions appear nodules within terminal respiratory bronchioles nodules dpb appear opaque lumps viewed xrays lung cause airway obstruction evaluated pulmonary function test lung xrays also reveal dilation bronchiolar passages another sign dpb hrct scans often show blockages bronchiolar passages mucus referred treeinbud hypoxemia another sign breathing difficulty revealed measuring oxygen carbon dioxide content blood using blood test called arterial blood gas findings observed dpb include proliferation lymphocytes white blood cells fight infection neutrophils foamy histiocytes tissue macrophages lung lining bacteria h influenzae p aeruginosa also detectable latter becoming prominent disease white blood bacterial cellular content blood measured taking complete blood count cbc elevated levels igg iga classes immunoglobulins may seen well presence rheumatoid factor indicator autoimmunity hemagglutination clumping red blood cells response presence antibodies blood may also occur neutrophils betadefensins leukotrienes chemokines also detected bronchoalveolar lavage fluid injected removed bronchiolar airways individuals dpb differential diagnosis finding correct diagnosis diseases overlapping features obstructive lung diseases dpb often considered number dpb symptoms resemble found obstructive lung diseases asthma chronic bronchitis emphysema wheezing coughing sputum production shortness breath common symptoms diseases obstructive respiratory functional impairment found pulmonary function cystic fibrosis like dpb causes severe lung inflammation excess mucus production infection dpb cause disturbances pancreas electrolytes cf two diseases different probably dpb distinguished presence lesions appear xrays nodules bronchioles lungs inflammation tissue layers respiratory bronchioles higher prevalence among individuals east asian dpb bronchiolitis obliterans two forms primary specific overlapping features diseases include strong cough large amounts often pusfilled sputum nodules viewable lung xrays lower bronchi bronchiolar area chronic sinusitis dpb nodules restricted respiratory bronchioles ob often found membranous bronchioles initial noncartilaginous section bronchiole divides tertiary bronchus secondary bronchus ob bronchiolar disease worldwide prevalence dpb localized prevalence predominantly prior clinical recognition dpb recent years often misdiagnosed bronchiectasia copd ipf phthisis miliaris sarcoidosis alveolar cell macrolide antibiotics erythromycin effective treatment dpb taken regularly extended period clarithromycin roxithromycin also commonly successful results macrolides dpb similar lung diseases stems managing certain symptoms immunomodulation adjusting immune achieved taking antibiotics low doses treatment consists daily oral administration two three years extended period shown dramatically improve effects dpb apparent individual undergoing treatment dpb among number diseaserelated remission criteria normal neutrophil count detected bal fluid blood gas arterial blood test measures amount oxygen carbon dioxide blood readings show free oxygen blood within normal allowing temporary break erythromycin therapy instances suggested reduce formation macrolideresistant p however dpb symptoms usually return treatment would need resumed although highly effective erythromycin may prove successful individuals disease particularly macrolideresistant p aeruginosa present previously untreated dpb progressed point respiratory failure erythromycin therapy dpb great reduction bronchiolar inflammation damage achieved suppression neutrophil proliferation also lymphocyte activity obstructive mucus water secretions antibiotic effects macrolides involved beneficial effects toward reducing inflammation evident treatment dosage much low fight infection dpb cases occurrence macrolideresistant p aeruginosa erythromycin therapy still reduces number factors involved suppression inflammation erythromycin macrolides especially effective inhibiting proliferation neutrophils diminishing ability interleukin leukotriene attract macrolides also reduce efficiency adhesion molecules allow neutrophils stick bronchiolar tissue linings mucus production airways major culprit morbidity mortality dpb respiratory diseases significant reduction inflammation dpb attributed erythromycin therapy also helps inhibit production excess untreated dpb leads bronchiectasis respiratory failure death journal report indicated untreated dpb fiveyear survival rate survival rate erythromycin treatment individuals dpb much longer life expectancy due better management symptoms delay progression prevention associated infections like p survival rate treated dpb dpb cases treatment resulted significant improvement sometimes happens two years treatment allowed end however individuals allowed stop treatment time closely monitored dpb proven recur erythromycin therapy must promptly resumed disease symptoms begin reappear spite improved prognosis treated dpb currently known dpb highest prevalence among japanese per individuals disease reported well genetic predisposition among east asians disease common male female ratio men average onset disease around age twothirds affected nonsmokers although smoking believed presence increases risk diffuse panbronchiolitis europe americas relatively small number dpb cases reported asian immigrants residents well individuals nonasian misdiagnosis occurred west owing less recognition disease asian countries relative large number asians living west small number thought affected dpb suggests nongenetic factors may play role cause rarity seen western asians may also partly associated early relatively new chronic lung disease observed described physicians japan name diffuse panbronchiolitis introduced distinguish chronic bronchitis emphysema alveolitis obstructive lung disease inflammation results nationwide survey initiated ministry health welfare japan revealed probable cases dpb histologically confirmed internationally recognized distinct disease prognosis expected outcome dpb poor especially cases superinfection emergence new viral bacterial infection addition currently occurring infection p dpb continued high mortality rate generalized antibiotic treatment oxygen therapy beginning used routinely effort manage symptoms around longterm treatment antibiotic erythromycin became standard managing dpb prognosis significantly association dpb hla initially httpsenwikipediaorgwikidiffusepanbronchiolitis